ELRIG announces keynote speakers for Therapeutic Oligonucleotides
ELRIG has announced that Professor Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, will provide the keynote talks at Therapeutic Oligonucleotides 2025.
The event ‘Therapeutic Oligonucleotides 2025: Drugging the Undruggable’ will take place at AstraZeneca in Gothenburg, Sweden from 14-15 May 2025.
This second ELRIG meeting on therapeutic oligonucleotides brings together scientists from academia, industry, and other members of the drug discovery community to explore the discovery, validation, and targeting of oligonucleotide-based drug candidates, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA).
The two-day event will delve into the nature of drug targets amenable to modulation by oligonucleotides, while comparing the advantages and limitations of these modalities with other drug types.
It will also cover recent advancements in broadening their application, including innovative approaches to ensure their safety and efficacy, the use of targeted delivery to reach disease-relevant tissues as well as success stories in bringing therapeutic oligonucleotides to the clinic.
In addition, the conference comprises poster presentations, networking sessions, a vendor exhibition and a tour of AstraZeneca’s R&D centre. There will also be a poster award for early-career professionals recognising the research that the next generation of scientists bring to drug discovery.
Professor Rory Johnson is an Associate Professor at University College Dublin, where his research focusses on uncovering the roles of long noncoding RNAs (lncRNAs) in human health and disease using an interdisciplinary combination of bioinformatic and experimental methods.
At AstraZeneca, Dr Shalini Andersson is Vice President Nucleic Acid Therapeutics in Discovery Sciences and Chief Scientist New Therapeutic Modalities in BioPharmaceuticals R&D. She is on the board of the Oligonucleotide Therapeutics Society, OligoNova (Sweden) and part of the scientific advisory group for the UK Nucleic Acid Therapeutics Accelerator.
Diana Spencer, Senior Digital Content Editor, DDW
